Who is sponsoring NCT03198559?

NCT03198559 is sponsored by University of Melbourne.

What condition does NCT03198559 study?

NCT03198559 studies HIV Infections.

What drugs are being tested in NCT03198559?

Interventions: Disulfiram, (National Drug Code) NDC 0378-4141-01, Vorinostat, NDC 00006-0568-40.

What is the status of NCT03198559?

NCT03198559 is currently TERMINATED.

Last reviewed 2024-02-09 · How we verify

Combination Latency Reversal With High Dose Disulfiram Plus Vorinostat in HIV-infected Individuals on ART

NCT03198559 PHASE1, PHASE2 TERMINATED Results posted

Antiretroviral therapy (ART) dramatically reduces Human Immunodeficiency Virus (HIV) replication leading to restoration of immune function and a near normal life expectancy, but treatment is lifelong and there is no cure. The major barrier to a cure is the persistence of long lived cluster of differentiation 4 (CD4+) T-cells that contain a "silenced" form of HIV, called HIV latency. The purpose of this research is to investigate whether it may be possible to reduce the amount of dormant HIV infection in immune cells, by "turning on" or activating the virus and hence force it out of the latently infected memory T cells. This leads to production of HIV by the cell, which will either die or will be recognized and eliminated by the immune system. As very few T cells are latently infected with HIV, the death of these cells is not expected to affect the function of the immune system and further infection of new cells is expected to be prevented by ART.

Details

Lead sponsor	University of Melbourne
Phase	PHASE1, PHASE2
Status	TERMINATED
Enrolment	5
Start date	Tue Aug 08 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Apr 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

HIV Infections

Interventions

Disulfiram, (National Drug Code) NDC 0378-4141-01
Vorinostat, NDC 00006-0568-40

Countries

Australia